Structure wobbles after softer-than-hoped-for oral GLP-1 data

19 December 2023
structure-tx-large-1

Hoping to capitalize on a  tsunami of interest in GLP-1 agonists for weight loss, Structure Therapeutics (Nasdaq: GPCR) has now published Phase IIa data for its oral candidate, but investors are not happy.

Shares in the company fell markedly following the release of a comprehensive development program update for its therapy, coded GSBR-1290.

The data show a significant impact on both HbA1c and weight reduction, compared to placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical